| 26.29 0.3 (1.15%) | 01-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 31.72  |
1-year : | 33.11 |
| Resists | First : | 27.16 |
Second : | 28.35 |
| Pivot price | 26.65 |
|||
| Supports | First : | 25.25 |
Second : | 21 |
| MAs | MA(5) : | 26.42 |
MA(20) : | 26.92 |
| MA(100) : | 24.27  |
MA(250) : | 21.57 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 33.3 |
D(3) : | 36 |
| RSI | RSI(14): 48.1 |
|||
| 52-week | High : | 28.35 | Low : | 13.39 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ACAD ] has closed above bottom band by 25.8%. Bollinger Bands are 51.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 26.35 - 26.5 | 26.5 - 26.63 |
| Low: | 24.87 - 25.06 | 25.06 - 25.23 |
| Close: | 26.01 - 26.29 | 26.29 - 26.55 |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Fri, 16 Jan 2026
Assessing Acadia Pharmaceuticals (ACAD) Valuation After New Long Term Sales And Pipeline Targets - Sahm
Fri, 16 Jan 2026
Investing in ACADIA Pharmaceuticals (NASDAQ:ACAD) a Year Ago Would Have Delivered You a 51% Gain - 富途资讯
Fri, 16 Jan 2026
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup - Chartmill
Thu, 15 Jan 2026
Is It Time To Reconsider ACADIA Pharmaceuticals (ACAD) After Recent Share Price Weakness - Sahm
Wed, 14 Jan 2026
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Sat, 20 Dec 2025
Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Its Strong 1-Year Share Price Rally - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 169 (M) |
| Shares Float | 125 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 101.6 (%) |
| Shares Short | 8,410 (K) |
| Shares Short P.Month | 8,910 (K) |
| EPS | 1.54 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.42 |
| Profit Margin | 24.9 % |
| Operating Margin | 12.8 % |
| Return on Assets (ttm) | 5.1 % |
| Return on Equity (ttm) | 34.9 % |
| Qtrly Rev. Growth | 11.3 % |
| Gross Profit (p.s.) | 3.65 |
| Sales Per Share | 6.2 |
| EBITDA (p.s.) | 0.64 |
| Qtrly Earnings Growth | 112.8 % |
| Operating Cash Flow | 199 (M) |
| Levered Free Cash Flow | 26 (M) |
| PE Ratio | 16.96 |
| PEG Ratio | 0 |
| Price to Book value | 4.85 |
| Price to Sales | 4.23 |
| Price to Cash Flow | 22.35 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|